Oxidized phospholipids (OxPLs) are a class of lipid mediators involved in diverse physiological and pathological processes.1 In particular, fragmented OxPLs on the surface of LDL can be formed via β-scission of the sn-2 fatty acid fragment on the glycerol backbone and are immunogenic.1,2 The E06 OxPL antibody clone tightly binds to copper-oxidized LDL, as well as copper-oxidized HDL, LDL modified with arachidonic acid or linoleic acid oxidation products, acrolein-LDL, and oxidized cardiolipin.3,4,2 It selectively binds to oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-PC (OxPAPC) over PAPC, 1-palmitoyl-2-arachidonoyl-sn-glycero-3-PE (PAPE), and OxPAPE.5 E06 has been used to detect phospholipid oxidation in atherosclerotic lesions in arteries isolated from LDL receptor-deficient rabbits.4 Cayman’s Oxidized Phospholipid Chimeric Rabbit Monoclonal Antibody (Clone E06) was produced recombinantly from the original E06 antibody sequence, substituting the mouse IgG1 variable domain of the E06 sequence for the rabbit IgGκ variable domain on a rabbit IgG antibody, and can be used for ELISA, flow cytometry (FC), functional assays, immunofluorescence (IF), immunohistochemistry (IHC), radioimmunoassay (RIA), and Western blot (WB) applications. The original E06 antibody was generated from ApoE-deficient mice fed a high-fat diet, which induces aortic atherosclerosis.4WARNING This product is not for human or veterinary use.
